Cancelled

Speakers

Expand/Collapse

Sheena Aurora
Medical Fellow Global Launch Leader Pain
Eli Lilly

Dr. Aurora received her medical degree from Christian Medical College in India. She interned at Wayne University in Detroit and completed her residency in Neurology at Henry Ford Hospital, also in Detroit. She then completed a fellowship in Headache and Neurophysiology at Henry Ford Hospital. Before coming to Lilly, she was Clinical Associate Professor of Neurology at Stanford University School of Medicine. She joined Lilly in April, 2016 as the Launch Leader for Galcanezumab. Dr. Aurora is board certified in neurology, headache management, and electro diagnostic medicine. She is an active member of several professional societies and has previously served as Chair of the American Academy of Neurology’s Headache Science Working Group; Co-Director of the American Headache Society’s Fall Symposium; and member of the Migraine Research Foundation’s Medical Advisory Board and the National Institute of Neurological Disorders and Stroke’s Working Group. She is also a former Secretary of the American Headache Society. Among Dr. Aurora’s many honors, she received the American Association for the Study of Headache’s Harold G. Wolff Award for Research in Headache (1999, 2001, 2007) and was selected to Seattle Magazine’s list of best doctors (2010, 2011, 2012 and on the list of best doctors in the San Francisco bay area 2015). Dr. Aurora has published more than 90 peer-reviewed manuscripts, most recently in The Journal of Pain, Headache, Acta Neurological Scandinavica, and Journal of Neurology, Neurosurgery, and Psychiatry. She was also one of the principal investigators of the first migraine program project funded by the National Institutes of Health. She lectures internationally on the topics of migraine, headaches, and pain. She continues to be an adjunct clinical associate professor in the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University in California.

Day One

Wednesday 12th December 2018

17.00 | Chair’s Closing Remarks

08.40 | Keynote: Migraine; From Hysteria to Neurobiological Entity

08.00 | Chair’s Opening Remarks

Day Two

Thursday 13th December 2018

16.30 | Chair’s Closing Remarks

09.00 | Chair’s Opening Remarks

Daniel Mikol
Executive Medical Director, Global Neuroscience Development
Amgen

Neuroscience Development lead: early/late stage migraine, pipeline products. Development lead for Erenumab (Aimovig) for migraine prevention.

Day One

Wednesday 12th December 2018

11.00 | Sharing Key Clinical Data from a CGRP Study, How is the Future Looking?

Michael Oshinsky
Program Director Pain & Migraine
National Institute of Health

Dr. Michael L. Oshinsky joined the NINDS in 2014 as a Program Director in Systems and Cognitive Neuroscience. Dr. Oshinsky received a B.A. in Biology with a concentration in Neuroscience from Brandeis University, where he learned electrophysiology in the laboratory of Eve E. Marder, Ph.D. He earned a Ph.D. in Neurobiology & Behavior from Cornell University in the laboratory of Ronald R. Hoy studying neural circuits. As an NIH sponsored postdoctoral fellow at the University of Pennsylvania, he trained with Gary Aston-Jones, Ph.D. in neuropharmacology and neuromodulation. He was on the faculty in the Department of Neurology at Thomas Jefferson University since 2001, before joining the NINDS. During those years he was the Director of Preclinical Research at the Jefferson Headache Center and directed an NIH funded research program aimed at developing and characterizing animal models of headache. In 2011, Dr. Oshinsky was award the Harold G. Wolff Award for headache research. He also taught in the Graduate Neuroscience Program and the Sydney Kimmel Medicine College at Thomas Jefferson University. As a Program Director at NINDS, Dr. Oshinsky is responsible for research and administrative issues related to migraine, other headache disorders, neuropathic pain, peripheral and central mechanisms that mediate pain, central processing of pain perception, disease-related pain disorders, and pain management.

Day One

Wednesday 12th December 2018

09.10 | Keynote: Exploring Opportunities for Funding for Translational Research in Migraine

Roger Cady
Vice President, Neurology
Alder Biopharmaceuticals

Dr. Cady has served as Vice President, Neurology of Alder BioPharmaceuticals since June 2016. Prior to joining Alder, Dr. Cady served as the Medical Director of the Headache Care Center and was the founder of Clinvest Research and Primary Care Network, a CME education company. He also served as Medical Director for the Shealy Institute in Springfield, Missouri. During his career, Dr. Cady has authored over 250 scientific papers and received numerous awards, including the Harold Wolff Award in 2000. Dr. Cady is also a Fellow of the American Headache Society and a member of the Board of Directors for the National Headache Foundation. Dr. Cady holds a bachelor’s degree from Drake University in Des Moines, Iowa and received his medical degree from the Mayo Medical School in Rochester, Minnesota. He then completed his residency in family practice at Mayo Clinic Health System – Franciscan Healthcare in La Crosse, Wisconsin.

Day One

Wednesday 12th December 2018

12.00 | Analysing Clinical Trial Data from Anti CGRP Monoclonal Antibodies Studies

Rami Burstein
Professor of Neuroscience
Harvard

Rami Burstein, Ph.D. is the John Hedley-Whyte Professor of Anaesthesia and Neuroscience at Harvard Medical School, and the Vice Chairman of Research in the Department of Anesthesia and Critical Care at Beth Israel Deaconess Medical Center.   Professor Burstein is an appointed member of the Interagency Pain Research Coordinating Committee (IPRCC), which consists of representative from the NIH, CDC, FDA and the Department of Health and Human Services and whose mission is to implement the Patient Protection and Affordable Care Act; and the current (Co)-Chairman of the Scientific Program Committee for the International Headache Conference meeting in 2019 and the European Headache Federation Annual Meeting in 2018.  He is a past member of the Board of Directors of both the American and the International Headache Societies. Throughout the years, he has received numerous awards.  These include the prestigious Javits Neuroscience Merit Award (National Advisory Neurological Disorder and Stroke Council), the Harold Wolff Awards for 2003 and 2005 (American Headache Society), the Cephalalgia Awards for best papers published in Cephalalgia in 2013 and 2015 (International Headache Society), the Seymour Diamond Lectureship Award in 2012 and 2015, and the 2010 Alan Edwards Center for Research on Pain Award )McGill University).  Among Professor Burstein accomplishments are the discoveries of the spinohypothalamic tract, peripheral and central sensitization role in migraine pathophysiology and treatment, mechanisms of action of several anti-migraine drugs, the neurobiology of photophobia, and most recently, the glymphatic system role in migraine. In the past 10 years, he has been serving as a reviewer for the NIH, the Welcome Trust, the Canadian Institute of Health Research, Science, the Dana Foundation Program in Brain and Immuno-imaging, Rita Allen Foundation, Brookdale Foundation, and the Ellison New Scholars Program in Aging.

Day One

Wednesday 12th December 2018

11.30 | Investigating CGRP Monoclonal Antibodies Mechanism of Action & What it Teaches Us About Migraine

Joshua Cohen
Global Therapeutic Area Lead for Migraine & Headache
Teva Pharmaceutials

Joshua M. Cohen, MD, MPH, FAHS is Board certified in Neurology and Headache Medicine. He was named in America’s Top Doctors in 2015, recognizing the top 1% of neurologists in the country.  He was also chosen as a Super Doctors® 2013 and 2014 New York Rising Stars.   Dr. Cohen is the Global Therapeutic Area Lead for Migraine & Headache at Teva Pharmaceuticals, Global Medical Affairs.  He is also serving as the launch lead for fremanezumab.  He has been at Teva for almost 3 years and had led the strategic development of a medical launch platform for fremanezumab. Dr. Cohen has been an active member of the American Medical Association for 19 years, serving in a variety of leadership positions including Chair of the Medical Student Section, Delegate to the House of Delegates as a member of the New York State Delegation, and Chair of the Young Physician Section's Committee on Maintenance of Certification and Maintenance of Licensure. He is also a leader in organized medicine on the state and local level, previously serving as President of the New York County Medical Society and currently as Commissioner for Public Health for the Medical Society of the State of New York (MSSNY). He has also worked extensively with non-profits dedicated to improving public health. Since 2013, he has served on the Board of Directors of the American Medical Association Foundation and just completed his term as President of that Foudation. He was a founding Board member of the Nan Lightstone Foundation whose mission is to support research and public education on infectious diseases. He served a two year term as Chair for Trevor Project NextGen, supporting that organization's work to provide suicide prevention and crisis intervention services to LGBTQ youth. Additionally, he was founder of Adolescents in Medicine at New York University, a program which encourages minority adolescents to pursue careers in healthcare fields, and he is also a former Albert Schweitzer Fellow. Dr. Cohen has published original research and book chapters on the headache disorders. He also serves as a frequent reviewer for the journals Headache and Cephalalgia, and he served as guest editor for an online edition of Headache on vestibular migraine. His interests are in the diagnosis and treatment of headaches in adolescents and adults, and in vestibular migraine. Dr. Cohen completed his undergraduate training at Harvard University, medical school at the New York University School of Medicine, and his neurology residency at Columbia University's Neurological Institute. He also trained at the Columbia Mailman School of Public Health where he received his Masters of Public Health. He completed his headache fellowship at The Headache Institute and a mini-fellowship in pediatric headache at Cincinnati Children's Hospital. He is the recipient of multiple awards and accolades, including the American Headache Society (AHS)/Merck US Human Health Scholarship Award, the Arnold P. Gold Foundation Humanism and Excellence in Teaching Award, and the Harvard University Derek Bok Center Teaching Award.

Day Two

Thursday 13th December 2018

09.10 | Designing a Medical Launch Strategy for a New Class of Migraine Therapeutics

Maria Jeleva
Associate Director Clinical Operations
Impel Neuropharma

Anil Namboodiripad
Senior Vice President
Dr Reddy’s

Mr. Anil Namboodiripad, Ph.D., has been the President & Senior Vice President of Proprietary Products at Promius Pharma, LLC since June 14, 2017. Mr. Namboodiripad serves as a Senior Vice President & Head-Proprietary Products at Dr. Reddy's Laboratories Limited. He has joined Dr. Reddy's Laboratories Limited in 2007 and in this role he is responsible for Proprietary Products business. He has been one of the main architects of Dr. Reddy's Laboratories Limited 's Proprietary Products business since July 2008, when systematic efforts towards differentiated formulations were first undertaken. He was responsible for leading external research and development and strategic marketing which included establishing research collaborations and “mini incubators” with various external industry partners and academic bodies. Over the years, his role has grown considerably with the inclusion of Proprietary Products drug development, regulatory affairs and the dermatology commercial effort under his leadership. Prior to joining us, he spent a number of years at Abbott Laboratories’s subsidiary Abbvie and at Bristol-Myers Squibb in various roles of increasing responsibility including strategic planning, corporate development and global commercial operations. leads strategy and execution of Promius Pharma’s clinical development stage pipeline as well as commercial operations for marketed products. He started his career as a management consultant with Booz & Co where he served clients on several high level business critical issues within financial services and healthcare. marketing. He holds Ph.D. in Physiology and Molecular Biophysics from the University of Texas

Day Two

Thursday 13th December 2018

11.00 | Reinvestigating Old Migraine Therapeutics, How Can They Be Improved

Todd Krueger
Chief Executive Officer
AO Biome

Todd Krueger  is the Chief Executive Officer, President and a Director of our Company. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015.  Mr. Krueger graduated from Northwestern University, United States, with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University, United States.

Day Two

Thursday 13th December 2018

09.40 | Identifying the Role of Ammonia Oxidizing Bacteria in the Prevention of Chronic Migraines

Shashidhar Kori
Chief Medical Officer
Trigemina

Shashidhar Kori, MD joined Trigemina as chief medical officer in 2015. He brought more than 30 years of research and drug development experience in neurosciences. Before joining Trigemina, he served as chief medical officer at Autonomic Technologies, Inc. (ATI), where he was responsible for clinical research, clinical outcomes and regulatory submissions. He oversaw development and execution of all clinical research, including ATI’s clinical trials in the United States and in Europe. Prior to Joining ATI, he was vice president of clinical development and medical affairs at Allergan. Prior to Allergan, Dr. Kori was vice president of clinical development and medical affairs at MAP Pharmaceuticals, where he built the Medical Affairs department from the ground up, helped submit an NDA and multiple INDs, ran clinical operations and oversaw an active publication strategy. Prior to his time at MAP, he was senior director of clinical development at GlaxoSmithKline (GSK). In this role, Dr. Kori oversaw the design and execution of clinical studies and coordinated responses to FDA for migraine and pain products in development. In addition, Dr. Kori participated in the development of new chemical entities and managed market support for marketed products.

Prior to GSK, Dr. Kori spent 24 years in academic medicine at major U.S. medical centers and universities (Sloan Kettering Cancer Center, Case Western Reserve University, Moffitt Cancer Center and Duke University) providing him with extensive experience in clinical patient care. In this capacity, he also founded and directed four major pain programs in the U.S.; taught students and residents and was voted “Best Teacher of the Year” four times (USF), performed research where he published more than 100 publications, several grants, described two new syndromes and devised a new questionnaire; and served in administration where he was director of a residency program, vice chairman of a department, chief of service and director of several clinical programs.

He also served as president, as a member of the board of directors and committee chair of several national professional societies (AAN, SPS, ASN, SEAPC), has delivered invited lectures in more than a dozen countries, chaired several national professional seminars and symposia, was visiting professor at 10 universities, was on the editorial board or medical reviewer for seven professional journals, and has significant media exposure (appearing on several national TV programs, radio programs and quoted in national publications).

Day Two

Thursday 13th December 2018

11.30 | Analysing Oxytocin for Migraine Prophylaxis: An Alternative or Complement to CGRP Antibodies?

Eric Liebler
Senior Vice President, Neurology
Electrocore

Eric brings more than 20 years of neurological industry and association experience to electroCore. In 2009, he co-founded Nautilus Neurosciences, a neurology-focused specialty pharmaceutical company focused on identifying and developing drugs benefiting those affected by neurological disorders, and brought to market Cambia® for the treatment of acute migraine. At Nautilus, Eric was involved in all facets of the company’s organization and early success, including initial funding, product commercialization, and sales and marketing. Eric has held leadership positions at Elan, Amarin, Enzon Pharmaceuticals, Questcor Pharmaceuticals, and Pharmacopeia. He founded Nisola LLC, an advocacy and business strategy consulting firm focused on serving clients in the field of neurology, and sat on the Board of Trustees of the American Academy of Neurology Foundation (now the American Brain Foundation) for more than a decade. Eric began his career at Athena Neurosciences, a pioneer in the development of neurology drugs, after graduating with honors from Tufts University.

Day One

Wednesday 12th December 2018

13.30 | A Device is Not a Drug - The Intersection of Clinical Development, Regulatory Approval & Commercial Success

Gabriel Vargas Executive Director
Medical, Mobile Health & Head of Neuroscience Therapeutic Area
Amgen

Gabriel obtained his undergraduate degree from the University of California at Berkeley where he majored in anthropology & genetics. He received his MD and PhD degrees from the University of California at Irvine and went on to complete a research track residency in Psychiatry at the University of California at San Francisco. After both a clinical and research fellowship he joined the faculty as an assistant professor in the Psychiatry Department where he spent 3 years leading a research group. After leaving academia in 2006 he spent five years at Roche the last 3 in Basel, Switzerland as head of the Neuroscience Clinical Biomarker Group where he worked on molecular and digital biomarkers. He joined Amgen in 2011 and leads a group of physician-scientists in Neuroscience and heads the Digital Medicine activities in Translational Medicine. He co-leads Amgen’s newly formed Clinical Technology & Experience Lab and has condcuted several digital medicine studies to test wearable sensors and devices and patient engagement technologies. He also led the early development for the CGRP receptor antagonist, AimovigTM, which was recently approved by the FDA for migraine prophylaxis.

Day One

Wednesday 12th December 2018

14.00 | Keeping Up With the Pace of Innovation in Migraine Drug Development

Mahmoud Ameri
Vice President Research & Development
Zosano

Dr. Ameri is one of the co-founders of Zosano Pharma, and brings 20 years of drug delivery, preclinical and early ex U.S. clinical development of combination products to the company. He is responsible for research and development. Prior to Zosano, he was at Alza/J&J were he co-invented and developed the Adhesive Dermally Applied Microarray system and holds over 20 patents and patent applications all relating to the Zosano drug delivery technology. Dr. Ameri received his PhD from the School of Pharmacy at the University of Manchester in the United Kingdom.

Day One

Wednesday 12th December 2018

14.30 | Exploring ADAM, a Novel Drug Delivery Platform for Treatment of Acute Migraine

Marcelo Bigal
Chief Medical Officer
Purdue

Dr. Marcelo E. Bigal is currently the Chief Medical Officer of Purdue pharma, overseeing the medical strategy and safety across all therapeutic areas and products. Before that, was the Chief Scientific Officer  and Head of Specialty Research Development at Teva, leading specialty research and development, including discovery, early and late stage clinical development, safety and pharmacovigilance, as well as global medical affairs. Areas of focus included pain and Headaches, Neurodegeneration and Movement Disorders, Psychiatry, and Respiratory, spamming over 31 clinical programs. Before thatheI was the Chief Medical Officer (CMO) and Head of the Global Specialty Development organization at Teva. Prior to Teva, he was the CMO at Labrys Biologics, Inc., leading the team responsible for the development of Fremanezumab, a humanized monoclonal antibody against CGRP, an anti-migraine and pain target. Prior to industry, Dr Bigal was a faculty member at the Albert Einstein College of Medicine, Department of Neurology, as well as the Director of Research at New England Center for Headache, Stamford, Connecticut and Director of Research at Montefiore Headache Center, Bronx, New York. He published over 325 peer-reviewed articles in indexed journals, edited six books and authored / co-authored 35 book chapters. Research focused on mechanisms of headache and pain progression and in the paradoxical effects of improper analgesic use in driving pain chronification. He hold numerous distinguished positions such as Scientific Director of the Annual Meeting of the American Headache Society (2005-2007) and Scientific Co-Director of the International Headache Congress (2007). I was also the Chairman of the Classification Committee of the American Headache Society and Chairman of the Acute Treatment Section of the Headache Standard Quality Committee of the American Academy of Neurology.  My most prestigious awards include the American Academy of Neurology Harold-Wolff John Graham Award for outstanding achievements in pain research (2005), the American Headache Society Wolff Award (2008), and the Cephalalgia Lecture Award for the most influential paper published in the Cephalalgia Journal in 2012 (2013).  Other awards include: International Headache Congress Award for Best Presentation to the Annual Meeting (2007), National Headache Foundation Annual Lecture Award (2008), American Headache Society Kapplan Award for best research in chronic daily headache (2004 and 2005),  and the American Headache Society Preventive Research Award (2005). Dr Bigal holds a Medical Doctorate degree from the College of Medicine at the University of São Paulo, Brazil, where I also obtained a Masters in Science and a Ph.D. in Neurosciences. I completed my post-doctoral research at the New England Center for Headache in Stamford, CT.

Day Two

Thursday 13th December 2018

13.30 | Examining Monoclonal Antibodies for Migraine – Lessons Learned in Epidemiology & Clinical

Maureen Moriarty
Associate Professor
Marymount University

Maureen Moriarty DNP, ANP-BC, FAHS obtained a graduate nursing degree in primary care of adults from the University of Maryland in 1986.  Since this time, her clinical practice, as a board certified nurse practitioner centers on care of patients with headache. This includes direct patient care, clinical research (both investigator and pharmaceutically initiated) and regional, national, and international educational offerings for provider and lay audiences on a variety of headache topics. She obtained a Doctor of Nursing Practice degree from Johns Hopkins University in 2010.  Her clinical research project focused on headache.  She was awarded the Nurse Practitioner of the Year award for the District of Columbia in 2015 from the American Association of Nurse Practitioners for excellent clinical work with headache patients.  Dr. Moriarty served as co-chair for the Nurse Practitioner/Physician Assistant (NP/PA) American Headache Society Special Interest Group from 2012-2016.  Under her direction “The Bridge Program” was developed.  Content in this one day seminar is targeted to NP’s and PA’s encountering headache complaints in primary care settings.  Since inception in 2016, the program has been successfully presented in multiple national venues.  Dr. Moriarty was inducted as a Fellow in the American Headache Society in 2017. In additional to an active clinical practice at MedStar Georgetown University Hospital since 2010, Dr. Moriarty continues to publish, research and speak nationally and internationally on headache related topics

Pre-Conference Workshop Day

Tuesday, December 11

13.00 | Workshop B

John Kollins
President & Chief Executive Officer
Satsuma Pharmaceuticals

Day Two

Thursday 13th December 2018

14.00 | Reflecting on Unmet Needs of the Acute Treatment in Migraine

Michael Rogawski
Founder
Epalex

MICHAEL A. ROGAWSKI is professor in the Department of Neurology with joint appointment in the Department of Pharmacology, and a member of the Center for Neuroscience at the University of California, Davis. Until 2006, he was senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. Dr. Rogawski received his B.A. from Amherst College, and M.D. and Ph.D. (pharmacology) from Yale University. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology, NINDS, he completed residency training in neurology at Johns Hopkins. Dr. Rogawski was chair of the UC Davis Department of Neurology until 2012. Dr. Rogawski’s research encompasses cellular neurophysiological studies of ion channels (with a focus on the mechanisms of action of antiepileptic drugs); animal models of epilepsy, migraine, and nerve agent intoxication; and clinical studies on new treatments for seizures, epilepsy, migraine, traumatic brain injury, and neurodevelopmental disorders. His laboratory studies on AMPA receptors and neurosteroids have led to new treatment approaches for seizures and epilepsy. Dr. Rogawski has received the NIH Director’s Award, the Epilepsy Research Award for Outstanding Contributions to the Pharmacology of Antiepileptic Drugs from the American Society for Pharmacology and Experimental Therapeutics, the Service Award from the American Epilepsy Society,  the American Academy of Neurology 2015 Neuroendocrine Research Award. and the Physician-Scientist Award of the End Epilepsy Summit, Epilepsy Foundation, Greater Los Angeles (April 2017). He presented the British Pharmacological Society Lecture, the Killam Lecture of the Montreal Neurological Institute, and the American Epilepsy Society’s William G. Lennox Lecture. Dr. Rogawski has served on the editorial boards of Molecular PharmacologyEpilepsiaEpilepsy ResearchSynapseCNS Drug ReviewsCurrent NeuropharmacologyPharmacology & TherapeuticsBMC PharmacologyCellular and Molecular Neurobiology, and Nature Scientific Reports, and was executive editor of Neuropharmacology and associate editor of Neurotherapeutics. He is a founder and was co-chief editor of Epilepsy Currents, the journal of the American Epilepsy Society. He is currently associate editor of Epilepsia Open. He has served on the board of directors of the American Epilepsy Society, he has been a member of advisory panels to the National Institutes of Health, and he serves in an advisory capacity as a special government employee to the Food and Drug Administration. He is past president of the American Society for Experimental NeuroTherapeutics.  

Day Two

Thursday 13th December 2018

16.00 | Identifying the Relationship of Epilepsy & Migraine

Melissa Darsey
Physcian
John R. Graham Headache Center Brigham and Women’s Faulkner Hosptial

Melissa Darsey, MPAS, PA-C, is a physician assistant at the John R. Graham Headache Center at Brigham and Women's Faulkner Hospital in Boston, Massachusetts. She graduated from Massachusetts College of Pharmacy and Health Sciences University in Boston, Massachusetts, and promptly entered into the headache field. In her clinical practice, she specializes in specific therapeutic interventions for management of different headache diagnoses, including migraine and cluster headache, as well as follow-up, urgent visits, and infusion center management for patients in the practice. She is also actively involved in coordinating research protocols at the Graham Headache Center.  

Pre-Conference Workshop Day

Tuesday, December 11

13.00 | Workshop B

Nim Lalvani
Director
American Migraine Foundation

Nim Lalvani has worked in patient engagement, patient programming, and patient advocacy for over twelve years. She has held patient-focused and leadership positions at organizations including the National Kidney Foundation, Young Survival Coalition, and New York State Health Foundation. She firmly believes in the mission of the American Migraine Foundation and feels that no one living with migraine should suffer in the dark. As the Director for the American Migraine Foundation, she plans to fully commit to the needs of patients affected by migraine and ensure that they have access to support, resources, and research that will empower them throughout their patient journey.

Pre-Conference Workshop Day

Tuesday, December 11

09.00 | Workshop A

Day Two

Thursday 13th December 2018

14.30 | Panel Discussion: Patient Advocate Perspective

Kirk Johnson
Senior Research Advisor
Eli Lilly

Kevin Lenaburg
Executive Director
Coalition For Headache And Migraine Patients CHAMP

Kevin’s connection to migraine disease is both personal and professional. He serves as the primary caregiver to a loved one with disabling chronic migraine and has witnessed their transition from being episodic (a few migraine attacks per month) to now having headache pain every day. Building from this personal experience and his passion to find better treatment options for migraine disease, Kevin now serves as the Executive Director of the Coalition For Headache And Migraine Patients (CHAMP).

Pre-Conference Workshop Day

Tuesday, December 11

09.00 | Workshop A

Day Two

Thursday 13th December 2018

14.30 | Panel Discussion: Patient Advocate Perspective